Latest Commercialisation News

Fortifai Limited has acquired an exclusive license to Nol8, a breakthrough real-time data processing technology developed by the Technion. This acquisition positions Fortifai to revolutionize data handling across gaming, AI, finance, and cybersecurity sectors.

Imricor Medical Systems has secured Institutional Review Board approval for the University of Virginia Health to join its VISABL-AFL clinical trial, marking a key expansion in the US. Procedures are set to begin early next year, supporting Imricor’s progress toward FDA approval and commercialisation.

Biome Australia has initiated its first human clinical trial for the proprietary probiotic strain Lactobacillus plantarum BMB18, aiming to validate its benefits for digestive and mood-related symptoms.

Echo IQ has formally lodged its FDA 510(k) submission for EchoSolv HF, an AI-driven heart failure diagnostic software validated by Mayo Clinic data, aiming to tap into a $60 billion US market.

New Frontier Minerals is wrapping up its first reverse circulation drilling at Harts Range, with samples now en route for assay analysis. Meanwhile, progress at the Big One Deposit mining lease signals advancing copper ambitions.

Elevate Uranium has successfully assembled its U-pgrade™ Demonstration/Pilot Plant in Namibia, with steady state operations expected to start in January 2026. This milestone aims to validate a proprietary beneficiation process that could transform uranium processing economics.

Metallium Limited has resumed trading on the ASX following news of a significant collaboration and funding deal with a US partner to advance its critical-metals recovery technology.

Metallium Ltd has secured a strategic partnership with ElementUSA to deploy its Flash Joule Heating technology for recovering gallium and scandium from red mud in Louisiana, backed by US$10.1 million in non-dilutive funding. This collaboration positions Metallium at the forefront of the US critical minerals supply chain expansion.

4DMedical has locked in $30.2 million through an underwriting agreement ensuring full exercise of its listed options, lifting its cash reserves to $63.7 million and setting the stage for a pivotal year in commercialising its CT – VQ™ technology.

Rhythm Biosciences has begun commercialising ColoSTAT®, its blood-based colorectal cancer diagnostic test, following an updated ISO15189, 2022 accreditation. The test offers a new option for symptomatic patients where stool-based screening is unsuitable.

Algorae Pharmaceuticals has unveiled breakthrough synergy predictions from its AI platform AlgoraeOS v2, spotlighting 90 high-potential CBD-drug combinations and surpassing models from Google DeepMind.

Skin Elements Limited has completed a $2.5 million placement to fund the commercial rollout of its ECO Nurture bio-stimulant, targeting sustainable kiwifruit orchard protection in New Zealand.